Abbott Reports First-Quarter 2025 Financial Results with Organic Sales Growth

Details

The company saw organic sales growth of 6.9% and reaffirmed its full-year 2025 financial guidance. Abbott's diversified business model contributed to top-tier sales and earnings per share (EPS) growth, with adjusted diluted EPS at $1.09. Key segments like Medical Devices and Nutrition saw significant growth, while Diagnostics sales were impacted by lower COVID-19 testing-related sales. The company also declared a quarterly dividend of $0.59 per share, marking 405 consecutive quarters of dividend increases.

Items reported

Exhibits (1)

About Abbott Laboratories

Abbott Laboratories, a globally renowned company, specializes in the development and production of healthcare and medical products. Founded in 1888 and headquartered in Abbott Park, Illinois, Abbott is a pivotal entity in the healthcare sector. The company provides essential products spanning diagnostics, medical devices, nutritional products, and branded generic pharmaceuticals. Notably, Abbott's extensive diagnostic solutions include immunoassays and molecular diagnostics, crucial for medical testing and healthcare management. Its medical devices division produces cardiovascular and neuromodulation products, enhancing patient care across diverse medical practices. Abbott’s nutritional segment, featuring well-known brands like Similac and Ensure, supports health and wellness across various demographics. Serving markets globally, Abbott Laboratories plays a critical role in advancing healthcare infrastructure and delivering innovative solutions that address evolving health challenges worldwide. As a significant player in the life sciences field, Abbott's contributions significantly influence patient outcomes and healthcare delivery systems.